Info

Santaris Pharma is a pioneer in the field of oligonucleotide drugs based on the third generation RNA chemistry, Locked Nucleic Acid (LNA), to which the company holds worldwide exclusive rights in therapeutics. Amongst several unique features, the LNA chemistry enables the development of oligonucleotides with unprecedented target affinity and bio-stability. We have termed such oligonucleotides "RNA Antagonists" to signal their potential to transform the future of oligonucleotide based drugs. Leveraging the LNA platform in cancer, we are researching and developing RNA Antagonists against genes that are central to tumour growth and malignant behaviour using both the antisense and siRNA principles. Santaris Pharma expects these novel drugs to improve the clinical outcomes for patients with malignant diseases and metabolic disorders.